Moderna plans mix of COVID-19 vaccine doses with new Lonza deal

It has agreed a deal with Swiss-based drugmaker Lonza which said a new drug substance production line in Geleen, Netherlands, will have capacity to make ingredients for up to 300 million doses annually at 50 micrograms per dose.

from International-News-Economic Times https://ift.tt/3pb4q8x
via IFTTT

SHARE